WO2005037231A3 - Methodes de detection et de traitement de la myopathie facioscapulohumerale - Google Patents
Methodes de detection et de traitement de la myopathie facioscapulohumerale Download PDFInfo
- Publication number
- WO2005037231A3 WO2005037231A3 PCT/US2004/034462 US2004034462W WO2005037231A3 WO 2005037231 A3 WO2005037231 A3 WO 2005037231A3 US 2004034462 W US2004034462 W US 2004034462W WO 2005037231 A3 WO2005037231 A3 WO 2005037231A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- muscular dystrophy
- methods
- detecting
- facioscapulohumeral muscular
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2878—Muscular dystrophy
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/686,491 | 2003-10-14 | ||
US10/686,491 US20050054012A1 (en) | 2002-10-11 | 2003-10-14 | Methods of detecting and treating facioscapulohumeral muscular dystrophy |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005037231A2 WO2005037231A2 (fr) | 2005-04-28 |
WO2005037231A3 true WO2005037231A3 (fr) | 2007-09-07 |
Family
ID=34465503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/034462 WO2005037231A2 (fr) | 2003-10-14 | 2004-10-14 | Methodes de detection et de traitement de la myopathie facioscapulohumerale |
Country Status (2)
Country | Link |
---|---|
US (1) | US20050054012A1 (fr) |
WO (1) | WO2005037231A2 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2175037B1 (fr) * | 2008-09-26 | 2017-10-11 | Genomic Vision | Procédé pour analyser les réseaux de répétitions en tandem du D4Z4 d'un acide nucléique et kit correspondant |
US10865445B2 (en) | 2010-08-18 | 2020-12-15 | Fred Hutchinson Cancer Research Center | Methods for alleviating facioscapulohumeral dystrophy (FSHD) by N siRNA molecule inhibiting the expression of DUX4-FL |
WO2013120038A2 (fr) * | 2012-02-10 | 2013-08-15 | Regents Of The University Of Minnesota | Morpholino ciblant le dux4 pour le traitement de la myopathie facio-scapulo-humérale |
WO2013155330A1 (fr) * | 2012-04-11 | 2013-10-17 | University Of Massachusetts | Compositions et procédés de caractérisation et de traitement d'une dystrophie musculaire |
WO2014071340A1 (fr) * | 2012-11-05 | 2014-05-08 | University Of Washington Through Its Center For Commercialization | Méthodes et dosages concernant la dystrophie musculaire facio-scapulo-humérale |
EP3532605A4 (fr) | 2016-10-26 | 2021-01-13 | Sonic Master Limited | Génération améliorée de cellules de lignée musculaire et leurs utilisations thérapeutiques |
-
2003
- 2003-10-14 US US10/686,491 patent/US20050054012A1/en not_active Abandoned
-
2004
- 2004-10-14 WO PCT/US2004/034462 patent/WO2005037231A2/fr active Application Filing
Non-Patent Citations (3)
Title |
---|
BLAIR ET AL.: "Identification, characterization, and association analysis of novel genes from the bipolar disorder susceptibility locus on chromosome 4q35", PSYCHIATRIC GENETICS, vol. 15, 2005, pages 199 - 204 * |
LYLE ET AL.: "The FSHD-associated repeat, D4Z4, is a member of a dispersed family of homeobox-containing repeats, subsets of which are clustered on the short arms of the acrocentric chromosomes", GENOMICS, vol. 28, 1995, pages 389 - 397 * |
WINOKUR ET AL.: "The evolutionary distribution and structural organization of the homeobox-containing repeat D4Z4 indicates a functional role for the ancestral copy in the FSHD region", HUMAN MOLECULAR GENETICS, vol. 5, 1996, pages 1567 - 1575 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005037231A2 (fr) | 2005-04-28 |
US20050054012A1 (en) | 2005-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003008623A3 (fr) | Analyse de methylation au moyen d'agents de synchronisation | |
WO2004113275A3 (fr) | Methodes et compositions pour traiter les maladies liees a l'amyloide | |
WO1999054286A3 (fr) | Inhibiteurs btk et leurs procedes d'identification et d'utilisation | |
AU2003294533A1 (en) | Molecular methods and compositions for detecting and quantifying respiratory viruses | |
WO2005111212A3 (fr) | Code-barres biologique | |
IL210632A0 (en) | Compositions and processes for analyte detection | |
NL1026892A1 (nl) | ó1,8!Naftyridin-2-onen en verwante verbindingen voor de behandeling van schizofrenie. | |
WO2002095396A3 (fr) | Dispositif d'essai en ligne et procedes d'utilisation | |
EP1700120A4 (fr) | Marqueur pour la neuromyelite optique | |
WO2004069184A3 (fr) | Procedes de traitement, de prevention et de diagnostic d'infections a helicobacter | |
IL173843A0 (en) | Assay for coronaviruses, reagents for use therein and kits containing the same | |
PT1560812E (pt) | Compostos de aminociclohexil eter e suas utilizacoes | |
AU2003297318A1 (en) | Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476. | |
WO2004064832A3 (fr) | Methodes pour traiter les douleurs articulaires ou ameliorer le sommeil a l'aide d'un agoniste/antagoniste des oestrogenes | |
WO2002098355A3 (fr) | Methodes et compositions pour diagnostic et traitement de la resistance a l'insuline et des etats associes | |
WO2005000208A3 (fr) | Therapie combinee pour le traitement des neoplasmes | |
WO2002039122A3 (fr) | Compositions et methodes permettant l'identification, l'evaluation, la prevention et la therapie des maladies cardio-vasculaires | |
WO2005037231A3 (fr) | Methodes de detection et de traitement de la myopathie facioscapulohumerale | |
WO2004105696A3 (fr) | Therapie combinatoire pour le traitement des neoplasmes | |
WO2002058533A3 (fr) | Procede pour determiner la fonction de cibles et identifier des tetes de serie de medicaments | |
WO2003087051A3 (fr) | Procedes d'identification de sites allosteriques | |
AU2003240558A1 (en) | Biological results evaluation method | |
WO2003017817A3 (fr) | Diagnostic, prevention et traitement du cancer | |
MXPA05009428A (es) | Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas. | |
AU2003258176A1 (en) | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |